
FDA Approves Tzield for Stage 3 Type 1 Diabetes Patients
The U.S. Food and Drug Administration has granted approval for the use of Tzield in patients aged 8 to 17 diagnosed with stage 3 type 1 diabetes. This marks a clinical shift, as the drug becomes the first disease-modifying therapy authorized to treat the condition's progression rather than merely managing symptoms.






















/bmi/media/post_banners/685374a708a95156958d6658a6e64c51d2d6e73262d48b69d1988c2ac58cb616.jpg)

